2024-03-28T15:12:13Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02016867
2022-02-22T07:17:41Z
1642838163960:1642838198944:1642838199408:1642838229560
1642838403551:1642838412624
[総説]神経膠芽腫に対するAkt を標的とした分子標的療法
[REVIEW]Targeted Molecular Therapy Against the Multiple Akt-mediated Signaling Pathways in Glioblastoma
渡邉, 孝
菅原, 健一
長嶺, 英樹
石内, 勝吾
Watanabe, Takashi
Sugawara, Kenichi
Nagamine, Hideki
Ishiuchi, Shogo
AMPA
Akt
glioblastoma
PI3K
platelet-derived growth factor
Glioblastoma multiforme is the most malignant tumor occurring in the central nervous system and is incurable by current therapeutic strategies. The serine/threoninespecific protein kinase, Akt, is frequently dysregulated and affects cell survival and proliferation in many human cancers, including glioblastoma. Inhibition of Akt phosphorylation has demonstrated therapeutic potential against glioblastoma. Many inhibitors of the PI3K-Akt signaling pathway and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-Akt signaling pathway are in clinical use and have demonstrated preliminary activity against various tumor types. This review describes the limitations of therapy against glioblastoma targeting single dysregulated pathways because of the presence of diverse signaling pathways that regulate the coactivation of multiple tyrosine kinases in most malignant gliomas, and the requirement for combined approaches targeting the multiple Akt-mediated signaling pathways based on the findings of clinical trials and earlier investigations.
論文
http://purl.org/coar/resource_type/c_6501
琉球医学会
Ryukyu Medical Association
VoR
1346-888X
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
1-3
33
7
1
jpn
open access